Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal triamcinolone before panretinal photocoagulation for diabetic macular edema in severe diabetic retinopathy
ACTRN12607000225415Phase 3Recruiting
- Sponsor
- Eye Research Center, Farabi Eye Hospital
- Start
- Nov 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of triamcinolone acetonide in diabetic macular edema (DME) and diabetic retinopathy (DR) (2 arms), sponsored by Eye Research Center, Farabi Eye Hospital. Primary endpoint: 10-letter improvement in visual acuity on ETDRS chart at 6 months. Started Nov 2005; status: recruiting.
02
Drugs
triamcinolone acetonide
03
Conditions
diabetic macular edema (DME)diabetic retinopathy (DR)
Beyond the preview
Go deeper on ACTRN12607000225415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000225415.